AUS
NZ
UK
CA
USA
IND
Headlines
- Solid Q2 Results: Eli Lilly surpassed expectations with $11.3 billion in revenue and adjusted earnings of $3.92 per share, prompting a 15% rise in its stock price.
- Exceptional Performance: The stock has seen a 455% increase since January 2021, outperforming the broader market and key competitors.
- Future Outlook: The company expects continued growth from its new products, with a raised full-year forecast reflecting optimism in its financial performance.
Eli Lilly's (NYSE:LLY) recent quarterly report has delivered impressive results, surpassing market expectations. The company announced revenues of $11.3 billion and adjusted earnings of $3.92 per share, well above the anticipated $9.9 billion and $2.60, respectively. Following this report, Eli Lilly’s stock surged more than 15%. This analysis examines Eli Lilly's recent stock performance, the highlights from its latest earnings report, and its future valuation.
Stock Performance Overview
Eli Lilly’s stock has shown remarkable growth, increasing by 455% from around $160 in early January 2021 to approximately $890 now. In contrast, the S&P 500 Index has risen about 40% over the same period. Eli Lilly has consistently outperformed the broader market over the last three years, with annual returns of 66% in 2021, 34% in 2022, and 61% in 2023. This performance stands out notably against other major companies in the Health Care sector and technology giants like Google, Tesla, and Microsoft. In comparison, the Trefis High Quality (HQ) Portfolio, which comprises 30 selected stocks, has also outperformed the S&P 500, showing better returns with less volatility.
Current Valuation and Growth Drivers
Given the current economic uncertainties, such as high oil prices and elevated interest rates, the future performance of Eli Lilly’s stock remains a point of interest. From a valuation standpoint, the stock appears to be fairly priced. However, strong demand for key drugs like Zepbound and Mounjaro is expected to support its stock value. Eli Lilly's Q2 revenue growth of 36% year-over-year can be attributed to market share gains for its drugs. Mounjaro saw a substantial increase in sales, tripling to $3.1 billion, while Verzenio and Zepbound also showed significant growth.
Future Expectations
Looking ahead, Eli Lilly’s new products are likely to drive further sales growth. The company projects a 75% increase in Mounjaro sales to around $1.8 billion and anticipates strong growth for Verzenio, with sales expected to exceed $1 billion. However, Zepbound may face challenges due to supply shortages. For 2024, Eli Lilly forecasts sales between $42.4 billion and $43.6 billion and adjusted earnings per share between $13.50 and $14.00. This is a notable improvement from 2023’s figures. Additionally, Eli Lilly has revised its full-year outlook upward, now expecting sales between $45.4 billion and $46.6 billion and adjusted earnings per share between $16.10 and $16.60. This upward revision reflects the company's positive performance and future growth expectations. Despite these developments, the stock appears to be appropriately valued at over $900.
